Lite Strategy (LITS) Assets Average (2011 - 2026)
Lite Strategy (LITS) posted Assets Average of $70.4 million for Q1 2026, down 28.3% on a QoQ basis from $98.1 million in Q4 2025, and up 211.59% year-over-year from $22.6 million in Q1 2025.
Analysis
Lite Strategy (LITS) Assets Average (2011 - 2026) Analysis & Trends
Lite Strategy has reported Assets Average for 16 years, with the latest figure at $70.4 million in Q1 2026.
- On a quarterly basis, Assets Average rose 211.59% year-over-year to $70.4 million in Q1 2026; TTM through Mar 2026 was $70.4 million, a 211.59% increase from a year earlier, with the FY2025 full-year figure at $29.8 million, down 63.21% from the prior year.
- Assets Average was $70.4 million for Q1 2026 at Lite Strategy, down from $98.1 million in the prior quarter.
- The five-year high for Assets Average was $201.9 million in Q1 2022, with the low at $19.5 million in Q2 2025.
- Average Assets Average over 5 years is $97.2 million, with a median of $89.9 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Assets Average plunged 71.0% in 2024, then soared 276.47% in 2025.
- Over 5 years, Assets Average stood at $155.6 million in 2022, then plunged by 42.22% to $89.9 million in 2023, then slumped by 71.0% to $26.1 million in 2024, then jumped by 276.47% to $98.1 million in 2025, then declined by 28.3% to $70.4 million in 2026.
- The last three Assets Average figures came in at $70.4 million (Q1 2026), $98.1 million (Q4 2025), and $65.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 70.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 70.36 Mn |
| Dec 31, 2025 | 98.14 Mn |
| Sep 30, 2025 | 65.81 Mn |
| Jun 30, 2025 | 19.53 Mn |
| Mar 31, 2025 | 22.58 Mn |
| Dec 31, 2024 | 26.07 Mn |
| Sep 30, 2024 | 34.56 Mn |
| Jun 30, 2024 | 56.32 Mn |
| Mar 31, 2024 | 74.90 Mn |
| Dec 31, 2023 | 89.89 Mn |
| Sep 30, 2023 | 111.03 Mn |
| Jun 30, 2023 | 127.50 Mn |
| Mar 31, 2023 | 140.89 Mn |
| Dec 31, 2022 | 155.59 Mn |
| Sep 30, 2022 | 170.71 Mn |
| Jun 30, 2022 | 186.13 Mn |
| Mar 31, 2022 | 201.95 Mn |
| Dec 31, 2021 | 192.91 Mn |
| Sep 30, 2021 | 175.22 Mn |
| Jun 30, 2021 | 180.11 Mn |